Public Contracts Scotland

NP49425 Generic and Biosimilar Transition Medicines

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Awarded
supplies
Scotland
10 lots

This tender has closed

The submission deadline for this contract has passed. There may be more active supplies tenders from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS), and hundreds more across the UK public sector.

Key details

Region
Scotland
Contract value
£78,009 - £26,539,272ex VAT
Submissions closed
Not stated by buyer
Published
19 December 2025

Procurement

Contract period
1 February 2026 - 28 February 2027
1 years
Procedure type
Open procedure
CPV classifications
  • 33600000 Pharmaceutical products

What happened

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) awarded this contract to Mercury Pharmaceuticals Limited | Celltrion Healthcare United Kingdom Limited | Fresenius Kabi Ltd | Roche Products Ltd | Janssen-Cilag Ltd | Accord Healthcare Ltd | Amarox Limited | AOP Orphan Ltd | Biocon Pharma UK Ltd | Celix Pharma Ltd. | Chiesi Limited | Dr Falk Pharma UK Ltd | Dr Reddy's Laboratories (UK) Ltd | Ferring Pharmaceuticals Limited | Glenmark Pharmaceuticals Europe Ltd | MSN Labs | Perennial Pharma Ltd | SERB SA | Takeda UK Limited | Teva UK Ltd | STADA UK - Thornton & Ross | Viatris UK Healthcare Ltd | Wockhardt UK Limited | Zydus Pharmaceuticals UK Ltd | Zentiva UK | Gedeon Richter UK Ltd | Samsung Bioepis Ltd | Sandoz | Vifor Pharma UK Limited | Brown and Burk | CST Pharma Ltd | Pfizer | Amgen Ltd | Lupin Healthcare UK Ltd worth £26,539,272 on 18 Dec 2025. The contract runs until 28 Feb 2027.

Description

Supply of generic and biosimilar transition medicines to NHS Scotland.

Full description

Supply of gastrointestinal, endocrine, blood, and multiple sclerosis medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Additional information

The estimated values referred to in Section II.I.7 and Section V.2.4 (and within all Lots) cover both the initial duration (which is variable, depending on the Lot) and the optional extension period (which is variable, depending on the Lot) -- covering a maximum total duration of forty-eight (48) months.

Details of individual product lines awarded within a specific Lot can be requested from the named person at the head of this notice.

Awarded suppliers (34)

Suppliers
  • Mercury Pharmaceuticals Limited
  • Celltrion Healthcare United Kingdom Limited
  • Fresenius Kabi Ltd
  • Roche Products Ltd
  • Janssen-Cilag Ltd
  • Accord Healthcare Ltd
  • Amarox Limited
  • AOP Orphan Ltd
  • Biocon Pharma UK Ltd
  • Celix Pharma Ltd.
  • Chiesi Limited
  • Dr Falk Pharma UK Ltd
  • Dr Reddy's Laboratories (UK) Ltd
  • Ferring Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Europe Ltd
  • MSN Labs
  • Perennial Pharma Ltd
  • SERB SA
  • Takeda UK Limited
  • Teva UK Ltd
  • STADA UK - Thornton & Ross
  • Viatris UK Healthcare Ltd
  • Wockhardt UK Limited
  • Zydus Pharmaceuticals UK Ltd
  • Zentiva UK
  • Gedeon Richter UK Ltd
  • Samsung Bioepis Ltd
  • Sandoz
  • Vifor Pharma UK Limited
  • Brown and Burk
  • CST Pharma Ltd
  • Pfizer
  • Amgen Ltd
  • Lupin Healthcare UK Ltd
Award value
£26,539,272
Award date
18 December 2025

Contact

Address
1 South Gyle Crescent, Edinburgh, EH12 9EB
Contact name
Stephanie Hammel

Identifiers

Notice ID
rls-24-DEC546134
OCID
ocds-r6ebe6-0000807501

Explore related tenders

Other tenders from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

View all →

External ID: pcs-ocds-r6ebe6-0000807501 • Added 15 May 2026